$200.00
Envío gratuito para pedidos superiores a 2.000 $
Precio por envase (10 viales). El descuento se aplica únicamente a este compuesto; no se admiten combinaciones.
| 10 mg | ||
|---|---|---|
| Cantidad | Precio por paquete | Ahorros |
| 1 paquete | 200 dólares por paquete | |
| 2 paquetes | 170 dólares por paquete | 15 % de descuento |
| 3 paquetes | 144 dólares por paquete | 28 % de descuento |
| 5 paquetes | 130 dólares por paquete | 35 % de descuento |
| 10 paquetes | 117 dólares por paquete | 42 % de descuento |
| 25 paquetes | 105 dólares por paquete | 48 % de descuento |
Melanotan 1 (MT-1), now known clinically as afamelanotide, is a synthetic linear analogue of alpha-melanocyte stimulating hormone (α-MSH) developed at the University of Arizona in the 1980s by researchers Mac Hadley and Victor Hruby. The natural α-MSH peptide has a plasma half-life of minutes; MT-1 was engineered with amino acid substitutions — most critically [Nle4, D-Phe7] — that extend metabolic stability while preserving receptor engagement. Unlike its cyclic counterpart Melanotan 2, MT-1 binds melanocortin-1 receptor (MC1R) with high selectivity, producing minimal activity at MC3R and MC4R. This receptor selectivity makes it the more targeted tool for photoprotection and pigmentation research.
MC1R is expressed primarily on melanocytes and governs the switch between eumelanin (brown/black) and phaeomelanin (red/yellow) synthesis. Selective MC1R agonism drives eumelanin production without the central nervous system side effects — nausea, spontaneous erection — associated with MC4R agonism. This selectivity is why afamelanotide (MT-1) reached clinical approval for erythropoietic protoporphyria (EPP) while MT-2 did not. Research applications requiring isolated pigmentation pathway activation without systemic melanocortin effects rely on this receptor profile.
| Mecanismo | Efecto |
|---|---|
| MC1R agonism → adenylyl cyclase / cAMP elevation | Upregulation of MITF transcription factor; melanogenesis induction |
| Eumelanin synthesis increase | UV-absorbing pigment accumulation in skin models |
| Phaeomelanin suppression (relative) | Shift toward photoprotective pigment type in melanocyte studies |
| Anti-inflammatory signaling (MC1R on immune cells) | NF-κB suppression; studied in photosensitivity and inflammatory skin models |
| Minimal MC3R/MC4R engagement | Reduced CNS and autonomic effects vs non-selective melanocortin agonists |
Melanotan 1 is used in studies examining:
| Formato | Polvo liofilizado |
| Pureza | ≥99% |
| Alias | MT-1, afamelanotide, melanotan I, [Nle4, D-Phe7]-α-MSH |
| Tallas disponibles | 10 mg |
| Almacenamiento | 2–8 °C sin abrir; estable durante más de 12 meses |
| Uso | Solo para fines de investigación — No apto para uso humano |
Melanotan 1 arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:
Total en mg ÷ Volumen añadido (mL) = Concentración (mg/mL)
Ejemplo: vial de 10 mg + 2 ml de agua destilada = solución de 5 mg/ml
El péptido reconstituido debe conservarse a una temperatura de entre 2 y 8 °C y utilizarse en un plazo de 28 a 30 días.
Published literature and clinical trial data provide context for research framework design. The approved clinical formulation (Scenesse) delivers afamelanotide as a 16mg subcutaneous implant released over approximately 60 days. Injection-based research frameworks have examined smaller, more frequent administrations.
Melanotan 1 is commonly paired in research settings with:
Cada lote tiene una pureza ≥99 %. Si sometes tu compuesto a un análisis independiente y los resultados no coinciden, envíanos el certificado de análisis (COA) y te concederemos un vale de compra sin hacerte preguntas.
